DNA-硫鸟嘌呤浓度与儿童及年轻成人急性淋巴细胞白血病复发风险的IPD荟萃分析
在诱导治疗结束(EOI)时微小残留病(MRD)阳性的839例患者中,wmDNA-TG每增加100 fmol/μg,复发特异性风险比(HRa)为0.87(95%CI 0.78-0.97;p=0.013);EOI MRD阴性患者中无此关联(p=0.76)。验证分析排除既往发表的北欧NOPHO ALL2008儿童队列后,EOI MRD阳性患者HRa为0.92(95%CI 0.82-1.03;p=0.15);若再排除非随机采样的英国队列,HRa为0.82(95%CI 0.68-0.99;p=0.044)。
要点
- EOI MRD阳性ALL患者中,wmDNA-TG每增加100 fmol/μg,复发风险显著降低(HRa 0.87)。
- EOI MRD阴性患者中未观察到DNA-TG与复发风险的关联。
- 验证分析排除北欧队列后关联减弱,再排除英国队列后关联恢复显著。
核心结论
- 在EOI MRD阳性的非高危ALL患者中,较高的wmDNA-TG与较低的复发风险相关。
- DNA-TG作为维持治疗强度生物标志物的临床价值可能因治疗方案骨架而异。
研究设计与样本
- 研究类型:个体患者数据(IPD)荟萃分析。
- 分析方法:队列分层Cox回归分析,校正性别、年龄和诊断时白细胞计数。
主要发现
- EOI MRD阳性患者(839例)中,wmDNA-TG每增加100 fmol/μg的复发特异性HRa为0.87(95%CI 0.78-0.97;p=0.013)。
- EOI MRD阴性患者中,wmDNA-TG与复发风险无显著关联(p=0.76)。
- 验证分析排除北欧NOPHO ALL2008儿童队列后,EOI MRD阳性患者HRa为0.92(95%CI 0.82-1.03;p=0.15)。
- 进一步排除英国队列(非随机采样)后,EOI MRD阳性患者HRa为0.82(95%CI 0.68-0.99;p=0.044)。
临床怎么用
- 对于EOI MRD阳性的非高危ALL患者,维持治疗期间监测wmDNA-TG可能有助于评估复发风险。
- DNA-TG的临床解读需考虑治疗方案骨架差异。
局限性
- 排除北欧队列后验证分析未达统计学显著性(p=0.15)。
- 英国队列样本为非随机选取,可能引入偏倚。
- DNA-TG的临床价值可能因治疗方案不同而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Methotrexate/6-mercaptopurine maintenance therapy improves acute lymphoblastic leukemia (ALL) outcome. Cytotoxicity is mediated by DNA incorporation of thioguanine nucleotides (DNA-TG). We investigated the association of DNA-TG to relapse risk in 1 910 children and young adults with non-high risk ALL. In a cohort-stratified Cox regression analysis adjusted for sex, age, and white cell count at diagnosis, the relapse-specific hazard ratio (HRa) per 100 fmol/μg increase in weighted mean DNA-TG (wmDNA-TG) was 0.87 (95% CI 0.78-0.97; p = 0.013) in the 839 patients who were minimal residual disease (MRD) positive at end of induction therapy (EOI), whereas this was not the case in EOI MRD-negative patients (p = 0.76). Validation analysis excluding the previously published Nordic NOPHO ALL2008 pediatric cohort yielded a HRa of 0.92 (95% CI 0.82-1.03; p = 0.15) per 100 fmol/μg increase in wmDNA-TG in EOI MRD-positive patients. If also excluding the United Kingdom cohort, in which samples were taken non-randomly in selected patients, the HRa for the EOI MRD-positive patients was 0.82 (95% CI 0.68-0.99; p = 0.044) per 100 fmol/μg increase in wmDNA-TG. The importance of DNA-TG as a biomarker for maintenance therapy intensity calls for novel strategies to increase DNA-TG, although its clinical value may vary by protocol backbone.
引用
- Toksvang LN, Grell K, Nersting J, et al. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis. Leukemia. 2021. PMID: 34175901. doi:10.1038/s41375-021-01182-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。